RxDoctor Payments Data

Michael Luther, PA

Physician Assistant · Troy, MINPI 1447337688

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $11,133 of the $14,484 with a category attached, or 76.9%. Johnson & Johnson accounts for 74.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $6,627 and has fallen 92.1% since, to $527 in 2025. Among physician assistant clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,484in general payments, 2019–2025

Across 60 payments — averaging $241.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$11K
  • Astellas Pharma US Inc$2K
  • Janssen Scientific Affairs, LLC$390
  • Gilead$234
  • Pfizer$177
  • Sobi, Inc$142
  • plus $419 from 9 others

What the payments were for

  • Consulting fees$3903%
  • Speaking & faculty fees$11,13377%
  • Travel & lodging$9977%
  • Food & beverage$1,73312%
  • Education$2322%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,484 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$19,920
Medicare patients
95
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide280$3,539,794
NubeqaDarolutamide71$849,162
Abiraterone Acetate239$453,033
OrgovyxRelugolix33$82,325
EliquisApixaban28$21,003
Prednisone247$1,322
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$599
Tamsulosin Hcl33$278
Ondansetron OdtOndansetron24$265
Methylphenidate Hcl20$258
Gabapentin25$227
Omeprazole15$113
Alendronate Sodium22$89
Dexamethasone18$70
Olanzapine11$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$2,398$3,539,794280 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$390$453,033239 claims
PfizerEliquis$177$21,00328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →